









Mercado
/
Acciones
/
nasdaq-abbv
/

AbbVie Inc

ABBV

228.070USD

+2.430+1.08%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

403.08BCap. mercado

171.83P/E TTM



AbbVie Inc

228.070

+2.430+1.08%

Descripción general Finanzas Análisis Compañía

Descripción general

Finanzas

Análisis

Compañía

Más Datos de AbbVie Inc Compañía

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

Información de AbbVie Inc



Símbolo de cotizaciónABBV

Nombre de la empresaAbbVie Inc

Fecha de salida a bolsaJan 02, 2013

Director ejecutivoMichael (Robert A)

Número de empleados55000

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 02

Dirección1 N Waukegan Rd

CiudadNORTH CHICAGO

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísUnited States of America

Código postal60064

Teléfono18479327900

Sitio Webhttps://www.abbvie.com/

Símbolo de cotizaciónABBV

Fecha de salida a bolsaJan 02, 2013

Director ejecutivoMichael (Robert A)

Ejecutivos de AbbVie Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+1203.00%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+1203.00%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+5877.00%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+1203.00%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+1203.00%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+1203.00%

Ms. Melody B. Meyer

Independent Director

16.50K

+1203.00%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-21250.00%

Ms. Jennifer L. Davis

Independent Director

2.52K

+1203.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+1203.00%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+1203.00%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+5877.00%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+1203.00%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+1203.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Immunology-SKYRIZI

4.71B

29.84%

Immunology-RINVOQ

2.18B

13.84%

Immunology-HUMIRA

993.00M

6.29%

Neuroscience-Botox Therapeutic

985.00M

6.24%

Neuroscience-Vraylar

934.00M

5.92%

Otro

5.97B

37.85%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

11.53B

73.07%

International

3.35B

21.21%

All other countries

660.00M

4.18%

Collaboration revenue

243.00M

1.54%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Immunology-SKYRIZI

4.71B

29.84%

Immunology-RINVOQ

2.18B

13.84%

Immunology-HUMIRA

993.00M

6.29%

Neuroscience-Botox Therapeutic

985.00M

6.24%

Neuroscience-Vraylar

934.00M

5.92%

Otro

5.97B

37.85%

Estadísticas de accionistas

Actualizado: dom., 16 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

5.25%

State Street Investment Management (US)

4.52%

Geode Capital Management, L.L.C.

2.29%

JP Morgan Asset Management

2.06%

Otro

75.70%

Accionistas

Proporción

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

5.25%

State Street Investment Management (US)

4.52%

Geode Capital Management, L.L.C.

2.29%

JP Morgan Asset Management

2.06%

Otro

75.70%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

43.82%

Investment Advisor/Hedge Fund

20.47%

Research Firm

3.08%

Bank and Trust

2.30%

Pension Fund

2.27%

Sovereign Wealth Fund

1.41%

Hedge Fund

0.92%

Insurance Company

0.70%

Family Office

0.20%

Otro

24.83%

Participación institucional



Actualizado: lun., 8 de dic

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

5311

1.33B

74.86%

+1.37M

2025Q3

5386

1.32B

74.95%

+8.86M

2025Q2

5326

1.32B

74.78%

+2.41M

2025Q1

5334

1.32B

74.15%

+3.84M

2024Q4

5267

1.31B

73.92%

+9.35M

2024Q3

4970

1.30B

74.13%

-1.24M

2024Q2

4907

1.30B

73.33%

+14.47M

2024Q1

4916

1.28B

72.48%

+1.37M

2023Q4

4861

1.27B

72.12%

+10.24M

2023Q3

4666

1.27B

72.28%

+8.75M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

176.93M

10.01%

+427.57K

+0.24%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

92.78M

5.25%

+679.67K

+0.74%

Sep 30, 2025

State Street Investment Management (US)

79.82M

4.52%

-202.47K

-0.25%

Sep 30, 2025

Geode Capital Management, L.L.C.

40.44M

2.29%

+1.26M

+3.22%

Sep 30, 2025

JP Morgan Asset Management

36.42M

2.06%

-1.05M

-2.81%

Sep 30, 2025

Charles Schwab Investment Management, Inc.

25.96M

1.47%

-825.22K

-3.08%

Sep 30, 2025

Capital Research Global Investors

25.23M

1.43%

-34.75K

-0.14%

Sep 30, 2025

Morgan Stanley Smith Barney LLC

23.97M

1.36%

+460.64K

+1.96%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

23.10M

1.31%

-1.99M

-7.94%

Jun 30, 2025

Fidelity Management & Research Company LLC

19.95M

1.13%

+301.27K

+1.53%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

VanEck Pharmaceutical ETF

9.64%

First Trust NASDAQ Pharmaceuticals ETF

8.05%

Health Care Select Sector SPDR Fund

7.89%

Proshares Ultra Health Care

7.62%

iShares U.S. Healthcare ETF

7.57%

JPMorgan Healthcare Leaders ETF

6.87%

Simplify Health Care ETF

6.73%

Fidelity MSCI Health Care Index ETF

6.5%

Harbor Health Care ETF

6.18%

iShares Core High Dividend ETF

5.9%

VanEck Pharmaceutical ETF

Proporción9.64%

First Trust NASDAQ Pharmaceuticals ETF

Proporción8.05%

Health Care Select Sector SPDR Fund

Proporción7.89%

Proshares Ultra Health Care

Proporción7.62%

iShares U.S. Healthcare ETF

Proporción7.57%

JPMorgan Healthcare Leaders ETF

Proporción6.87%

Simplify Health Care ETF

Proporción6.73%

Fidelity MSCI Health Care Index ETF

Proporción6.5%

Harbor Health Care ETF

Proporción6.18%

iShares Core High Dividend ETF

Proporción5.9%

Dividendos



Un total de 40.87B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Oct 31, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option

Jan 16, 2026

Feb 17, 2026

Jan 16, 2026

Sep 05, 2025

ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option

Oct 15, 2025

Nov 14, 2025

Oct 15, 2025

Jun 20, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option

Jul 15, 2025

Aug 15, 2025

Jul 15, 2025

Feb 13, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option

Apr 15, 2025

May 15, 2025

Apr 15, 2025

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

